Kexing Biopharm Management
Management criteria checks 4/4
Kexing Biopharm's CEO is Yanqing Zhao, appointed in Jul 2019, has a tenure of 6.42 years. directly owns 0.038% of the company’s shares, worth CN¥2.49M. The average tenure of the management team and the board of directors is 5.8 years and 6.4 years respectively.
Key information
Yanqing Zhao
Chief executive officer
CN¥1.1m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 6.4yrs |
| CEO ownership | 0.04% |
| Management average tenure | 5.8yrs |
| Board average tenure | 6.4yrs |
Recent management updates
Recent updates
Market Might Still Lack Some Conviction On Kexing Biopharm Co., Ltd. (SHSE:688136) Even After 26% Share Price Boost
Mar 29
There's No Escaping Kexing Biopharm Co., Ltd.'s (SHSE:688136) Muted Revenues Despite A 31% Share Price Rise
Dec 27There's No Escaping Kexing Biopharm Co., Ltd.'s (SHSE:688136) Muted Revenues Despite A 36% Share Price Rise
Oct 08Kexing Biopharm Co., Ltd.'s (SHSE:688136) Share Price Boosted 36% But Its Business Prospects Need A Lift Too
May 21Shandong Kexing Bioproducts Co,.Ltd (SHSE:688136) Held Back By Insufficient Growth Even After Shares Climb 25%
Mar 08CEO
Yanqing Zhao (43 yo)
Mr. Yanqing Zhao is CEO, GM & Director of Kexing Biopharm Co. Ltd. from July 29, 2019.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, GM & Director | 6.4yrs | CN¥1.08m | 0.038% CN¥ 2.5m | |
| CFO, Secretary to the Board & Director | 6.4yrs | CN¥751.30k | 0.020% CN¥ 1.3m | |
| Deputy GM & GM of Technology Center | 5.3yrs | CN¥838.50k | 0.018% CN¥ 1.1m | |
| Deputy GM & Director | 6.4yrs | CN¥698.30k | 0.016% CN¥ 1.0m | |
| Deputy General Manager | 4.9yrs | CN¥1.25m | 0.045% CN¥ 2.9m | |
| Deputy General Manager | 4.9yrs | CN¥3.01m | 0.063% CN¥ 4.1m |
Experienced Management: 688136's management team is seasoned and experienced (5.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, GM & Director | 6.4yrs | CN¥1.08m | 0.038% CN¥ 2.5m | |
| CFO, Secretary to the Board & Director | 6.4yrs | CN¥751.30k | 0.020% CN¥ 1.3m | |
| Deputy GM & Director | 6.4yrs | CN¥698.30k | 0.016% CN¥ 1.0m | |
| Chairman of the Board | 6.4yrs | no data | 51.18% CN¥ 3.3b |
Experienced Board: 688136's board of directors are considered experienced (6.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/05 04:34 |
| End of Day Share Price | 2025/12/05 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kexing Biopharm Co., Ltd. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kai Wang | Citic Securities Co., Ltd. |
| Song Yang | Tianfeng Securities Brokerage Co., Ltd |